



FY 2026 Earnings Presentation

Q3

Presented by
Dr. Jennifer Bath, CEO



Date: 03.12.26

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of MindWalk Holdings Corp. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company’s most recent Annual Information Form, which is available under the Company’s profile on EDGAR at www.sec.gov/edgar and SEDAR+ at www.sedarplus.ca for additional related risks factors that could materially affect the Company’s operations and financial results.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise accept as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Intro

Q3 2026

was a milestone quarter
for MindWalk

**Consecutive
revenue growth**

Third quarter of YOY growth



**First
enterprise
contract**



Pipeline advancements
**3 assets in
development**



Third quarter consecutive YoY revenue growth

+ Revenue up 52% year-over-year
+ US revenue doubled



North America and AI-driven discovery demand is rising

First Enterprise Contract



+ Largest *in silico* client signed a one year LensAI™ platform contract

- + The one year contract is structured as:
- Recurring monthly revenue
 - Model we are scaling

LensAI™ Platform Q3 updates

+ **Functional adjacency capability advancement**

Identify molecules that produce the same therapeutic effect with very low sequence similarity

+ **Influenza Program:**

- Screening +2,000 diverse influenza sequences
- Spanning influenza A, influenza B, avian, and swine strains

Identifying a single conserved biological feature present in all

Pipeline Advancements

Utilizing LensAI™ powered by HYFT®s




Dengue

- + 390M people infected annually | WHO top 10 global health threat
- + We identified a single conserved epitope, 1 molecular target across all 4 serotypes



GLP-1

- + In a head-to-head *in vitro* testing, our candidate activated the GLP-1 receptor more effectively than semaglutide.
- + Additionally, molecule linked to a non-overlapping longevity pathway



Universal Influenza

- + Identified a single conserved functional constraint across: influenza A, influenza B, avian, and swine strains



Quarterly operational highlights

+ US revenue **doubled YoY**

+ Ended **Q3 with \$14.2 million dollars** in cash

+ Netherlands divestiture proceeds being **reinvested into growth and R&D**

+ Published peer-reviewed study in Biomacromolecules: **Nanobody Discovery**

+ Announced results on: **TDP43 advancements**

+ **B cell Llama™ launch**
Purpose-built for large industry need: bispecific antibodies, multispecific therapeutics, and CAR-T therapies.




Financial Update

FY 2026 Earnings Presentation


Q3

Revenue by period

(All values in CAD, in thousands)




Continued YoY Revenue Growth



Cash balances

- + Continue to manage cash
- + Capital allocation for strategic initiatives





Thanks

Contact: info@mindwalk.com

MindWalkai.com

NASDAQ:HYFT | ir.mindwalkai.com | Mindwalkai.com

Questions

FY 2026 Earnings Presentation

Q3